The attitude of young people to smoking electronic cigarettes. Pharmacotherapy of nicotine addiction

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

A review of information on the increasing use of electronic smoking products in modern society - vapes (including electronic cigarettes - ES), their characteristics (structure, composition, mechanism of action, effect on the body) is given. The data of studies that have shown that ES, especially nicotine-containing, have numerous negative effects on many organs and tissues of vapers are presented. The results of our own research on the attitude of students to electronic cigarettes are included. It is shown that a significant part of the respondents are critical of their use, believing that ES are harmful to health, involve young people in the process of smoking and conventional cigarettes. Various strategies for the treatment of nicotine addiction (pharmacological and non-drug) are highlighted. As a pharmacological correction, the possibility of nicotine and nicotine-free pharmacological therapy is considered. It is recommended to include psychological and behavioral and alternative therapy in the arsenal of non-drug correction.

全文:

受限制的访问

作者简介

T. Potupchik

V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of the Russia

Email: potupchik_tatyana@mail.ru
Candidate of Medical Sciences

L. Evert

Federal Research Center «Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences», Scientific Research Institute of Medical Problems of the North; N.F. Katanov Khakass State University of the Ministry of Science and Higher Education of the Russian Federation

Email: potupchik_tatyana@mail.ru

доктор медицинских наук

Yu. Kostyuchenko

Federal Research Center «Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences», Scientific Research Institute of Medical Problems of the North

Email: potupchik_tatyana@mail.ru

A. Ilyashevlch

V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of the Russia

Email: potupchik_tatyana@mail.ru

M. Tkach

V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of the Russia

编辑信件的主要联系方式.
Email: potupchik_tatyana@mail.ru

参考

  1. Гамбарян М.Г. Вся правда об электронных сигаретах: Российская реальность. Часть I. Электронные сигареты - угроза для людей и антитабачной политики в России. Актуальность правового регулирования. Профилактическая медицина. 2019; 22 (5): 7-15 doi: 10.17116/profmed2019220517
  2. Гамбарян М.Г., Калинина А.М., Попович М.В. и др. Вся правда об электронных сигаретах: Российская реальность. Часть III. Поддержка законодательного регулирования электронных сигарет населением России. Результаты репрезентативного опроса взрослого населения ЭПОХА-РФ. Профилактическая медицина. 2020; 23 (1): 23-34 doi: 10.17116/profmed20202301123
  3. Государственный реестр лекарственных средств [State Register of Medicines (in Russ.)]. URL: http://sites.reformal.ru/grls.rosminzdrav.ru/
  4. Менделевич В.Д. Польза и вред электронных сигарет сквозь призму разных терапевтических методологий. Вестник современной клинической медицины. 2015; 8 (2): 62-72
  5. Оценка химического состава электронных сигарет. Практическая пульмонология. 2015; 3: 77-8
  6. Петрейкин И.Ю., Петрейкина К.С. Чему отдает предпочтение молодежь: обычным сигаретам или электронным? Международный студенческий научный вестник. 2019; 2 [Petreykin I.Yu., Petreykina K.S. What do young people prefer: regular cigarettes or electronic ones? International Student Scientific Bulletin. 2019; 2 (in Russ.)]. Available at: https://eduherald.ru/ru/article/view?id=19587
  7. Прекращение потребления табака и лечение табачной зависимости: научно обоснованные рекомендации. Под ред. А.К. Демина. М.: Вашингтон, 2013
  8. Скворцова Е.С., Мамченко М.М. Курение электронных сигарет как медико-социальная проблема. Профилактическая медицина. 2021; 24 (8): 89-94 doi: 10.17116/profmed20212408189
  9. Сперанская О.И., Смирнов B. К., Богданов К.А. Первичная и вторичная терапевтическая резистентность к никотинзаместительной терапии у лиц с табачной зависимостью. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013; 113 (9): 59-62
  10. Электронные системы доставки никотина и электронные системы доставки продуктов, не являющихся никотином. Доклад ВОЗ. FCTC/ COP/7/11 август 2016 г. [Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems (ENDS/ENNDS) Report by WHO. FCTC/ COP/7/11 August 2016. (in Russ.)]. URL: https://www.who.int/fctc/cop/cop7/FCTC_ COP_7_11_RU.pdf
  11. Электронные системы доставки никотина: доклад ВОЗ. М., 2014 [Electronic nicotine delivery systems: WHO report. M., 2014 (in Russ.)]. URL: http://apps.who.int/gb/fctc/PDF/cop6/FCTC_COP6_10-ru.pdf
  12. Adkison S.E., O’Connor R.J., Bansal-Travers M. et al. Electronic nicotine delivery systems: international tobacco control four-country survey. Am J. Prev Med. 2013; 44: 207-15. doi: 10.1016/j.amepre.2012.10.018
  13. Ahmad S., Zafar I., Mariappan N. et al. Acute pulmonary effects of aerosolized nicotine. Am J. Physiol Lung Cell Mol Physiol. 2019; 316: L94-L104. doi: 10.1152/ajplung.00564.2017
  14. Beard E., McNeill A., Aveyard P. et al. Use of nicotine replacement therapy for smoking reduction and during enforced temporary abstinence: a national survey of English smokers. Addiction. 2011; 106 (1): 197-204. doi: 10.1111/j.1360-0443.2010.03215.x
  15. Bedell S., Wells J., Liu Q. et al. Vitexin as an active ingredient in passion flower with potential as an agent for nicotine cessation: vitexin antagonism of the expression of nicotine locomotor sensitization in rats. Pharm Biol. 2019; 57 (1): 8-12. doi: 10.1080/13880209.2018.1561725
  16. Bowler R.P., Hansel N.N., Jacobson S. et al. Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from Two Observational Cohorts. J. Gen Intern Med. 2017; 32: 1315-22. doi: 10.1007/s11606-017-4150-7
  17. Breland A.B., Almond L., Kienzle J. et al. Targeting tobacco in a community-based addiction recovery cohort: results from a computerized, brief, randomized intervention trial. Contemp Clin Trials. 2014; 38 (1): 113-20. DOI: 10.1016/j. cct.2014.03.008
  18. Bruijnzeel A.W. Neuropeptide systems and new treatments for nicotine addiction. Psychopharmacology (Berl). 2017; 234 (9-10): 1419-37. DOI: 10.1007/ s00213-016-4513-5
  19. Bullen C., Howe C., Laugesen M. Electronic Cigarettes for Smoking Cessation: A Randomised Controlled Trial. J. Vasc Surg. 2014; 59 (3): 872. doi: 10.1016/j.jvs.2014.01.028
  20. Cahill K., Lindson-Hawley N., Thomas K.H. et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016; 2016 (5): CD006103. doi: 10.1002/14651858.CD006103.pub7
  21. Cahill K., Stevens S., Perera R. et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013; 2013 (5): CD009329. doi: 10.1002/14651858. CD009329.pub2
  22. Di Matteo V., Pierucci M., Di Giovanni G., et al. The neurobiological bases for the pharmacotherapy of nicotine addiction. Curr Pharm Des. 2007; 13 (12): 1269-84. doi: 10.2174/138161207780618920
  23. Duffney P.F., McCarthy C.E., Nogales A. et al. Cigarette smoke dampens antiviral signaling in small airway epithelial cells by disrupting TLR3 cleavage. Am J. Physiol Lung Cell Mol Physiol. 2018; 314 (3): L505-L513. DOI: 10.1152/ ajplung.00406.2017
  24. Etter J.-F. Electronic cigarettes: a survey of users. BMC Public Health. 2010; 10: 231. doi: 10.1186/1471-2458-10-231
  25. Etter J.-F., Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. 2011; 106 (11): 2017-28. doi: 10.1111/j.1360-0443.2011.03505.x
  26. Fiore M.C., Jaen C.R. Treating tobacco use and dependence: 2008 Update A U.S. Public Health Service report. Am J. Prev Med. 2008; 35: 158-76.
  27. Fiore М.С., Baker T.B. Treating Smokers in the Health Care Setting. N. Engl J.Med. 2011; 365: 1222-31. doi: 10.1056/NEJMcp1101512
  28. Giulietti F., Filipponi A., Rosettani G. et al. Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice. High Blood Press Cardiovasc Prev. 2020; 27 (5): 349-62. doi: 10.1007/s40292-020-00396-9
  29. Hammond D., Reid J.L., Rynard V.L. et al. Prevalence of vaping and smoking among adolescents in Canada, England, and the United States: repeat national cross sectional surveys. BMJ. 2019; 365: l2219. doi: 10.1136/bmj.l2219
  30. Heydari G., Marashian M., Ebn Ahmady A. et al. Which form of nicotine replacement therapy is more effective for quitting smoking? A study in Tehran, Islamic Republic of Iran. East Mediterr Health J. 2012; 18 (10): 1005-10. doi: 10.26719/2012.18.10.1005
  31. Houezec J.L. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. Int J. Tuberc Lung Dis. 2003; 7 (9): 811-9. doi: 10.1186/1471-2458-10-231
  32. Islam N., Rahman S. Improved treatment of nicotine addiction and emerging pulmonary drug delivery. Drug Discov Ther. 2012; 6 (3): 123-32.
  33. Marketers of electronic cigarettes should halt unproved therapy claims. World Health Organization. Accessed May 27, 2020. URL: https://www.ivyroses.com/Health/2206
  34. McNeill A., Brose L.S., Calder R. et al. Vaping in England, an evidence updates, February 2019. A report commissioned by Public Health England. London: Public Health England, 2019. Accessed September 9, 2019. URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/821179/Vaping_in_England_an_evidence_update_September_2019.pdf
  35. Middlekauff H.R. Cardiovascular impact of electronic-cigarette use. Trends Cardiovasc Med. 2019; 30 (3): 133-40. doi: 10.1016/j.tcm.2019.04.006
  36. Ozarowski M., Mikolajczak P.L., Thiem B. Medicinal plants in the phytotherapy of alcohol or nicotine addiction. Implication for plants in vitro cultures. Przegl Lek. 2013; 70 (10): 869-74.
  37. Pedersen S.T., Christensen H.R., Dossing M. Treatment of nicotine addiction. Drug therapy for smoking cessation. Ugeskr Laeger. 2002; 164 (11): 1480-4.
  38. Position Statement on Electronic Cigarettes [ECs] or Electronic Nicotine Delivery Systems [ENDS], International Union Against Tuberculosis and Lung Disease, 44th Union World Conference on Lung Health, Paris, 3 November 2013.
  39. Raleigh M.D., Beltraminelli N., Fallot S. et al. Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies. PLoS One. 2021; 16 (7): e0254247. doi: 10.1371/journal.pone.0254247
  40. Ruszkiewicz J.A., Zhang Z., Gonalves F.M. et al. Neurotoxicity of e-cigarettes. Food Chem Toxicol. 2020; 138: 111245. DOI: 10.1016/j. fct.2020.111245
  41. Sliwinska-Mosson M., Zielen I., Milnerowicz H. New trends in the treatment of nicotine addiction. Acta Pol Pharm. 2014; 71 (4): 525-30.
  42. Smith L.C., George O. Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models. Neuropharmacology. 2020; 178: 108225. doi: 10.1016/j.neuropharm.2020.108225
  43. Thisted T., Biesova Z., Walmacq C. et al. Optimization of the enzyme that decomposes nicotine for potential use in the treatment of nicotine addiction. BMC Biotechnol. 2019; 19 (1): 56. doi: 10.1186/s12896-019-0551-5
  44. Uruma R. Smoking cessation for COPD. Nihon Rinsho. 2016; 74 (5): 783-8.
  45. Zhao Z., Powers K., Hu Y. et al. Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density. Biomaterials. 2017; 123: 107-17. doi: 10.1016/j.biomaterials.2017.01.038

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2022
##common.cookie##